Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Xin He,Dongyue Yang,Lingyao Lai,Jing Lang,Kebo Wei,Min Xiao
DOI: https://doi.org/10.2147/ccid.s458592
2024-03-09
Clinical Cosmetic and Investigational Dermatology
Abstract:Xin He, 1, 2 Dongyue Yang, 1, 2 Lingyao Lai, 1, 2 Jing Lang, 1, 2 Kebo Wei, 1, 2 Min Xiao 1 1 Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China; 2 School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China Correspondence: Min Xiao, Email Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system, and environmental triggers. The pathogenesis of this condition is still unclear, leading to unsatisfactory current treatments and causing a large number of patients to suffer from it. Janus kinase inhibitors are a new class of drugs that have emerged in recent years and are expected to be promising therapeutic tools for alopecia areata. We report five patients with varying backgrounds and severity of alopecia areata. All of them had received conventional therapy without success. Five patients took Upadacitinib at a dose of 15 mg once daily, and all of them achieved satisfactory efficacy. No adverse events were observed during the treatment of 5 patients. Keywords: upadacitinib, alopecia areata, JAK inhibitors, JAK-STAT Alopecia Areata (AA) is a prevalent inflammatory non-scarring alopecia condition. 1 It is currently considered a follicle-specific autoimmune disease resulting from a combination of genetic and environmental factors. The disease often presents as a sudden onset of round, flaky alopecia on the scalp with clear borders and localized smooth skin in the affected area, often without accompanying symptoms. In severe cases, there may be complete hair loss, including eyebrow, axillary, and pubic hair, leading to generalized or total baldness. This condition impacts the appearance and typically affects young and middle-aged individuals, often imposing a significant psychological and economic burden on patients. Traditional treatments include the topical and intradermal injection of glucocorticoids, topical minoxidil, and systemic use of glucocorticoids and immunosuppressants, among others. The clinical efficacy of these treatments varies greatly among individuals. The use of glucocorticoids and immunosuppressants has many side effects, leading to some patients still experiencing recurrent episodes of baldness after treatment. Fortunately, in recent years, studies have reported a number of new treatments for this disease, including oral Janus kinase inhibitors (JAK inhibitors, JAKi), antihistamines, compounded glycyrrhizin, and phototherapy. 2 Current research suggests that the development of this disease is associated with cytokines such as interferon (IFN), interleukin (IL), and CD8+ T cells. 3 The JAK-STAT signaling pathway is a common downstream signaling pathway for cytokines such as interferon and some interleukins (3). Therefore, regulating Janus kinase in the JAK-STAT signaling pathway may offer new insights and methods for treating AA. Numerous studies and clinical trials have shown that first-generation JAK inhibitors, such as Baricitinib and Tofacitinib, have demonstrated significant clinical efficacy for AA. However, their adverse effects are also noteworthy, and the FDA has issued a black box warning for medication safety. As a second-generation JAK inhibitor, Upadacitinib offers a higher level of selective inhibition of JAK1 and a better safety profile compared to first-generation drugs. It may potentially be a superior solution for the treatment of AA. 4 Therefore, we treated five patients with diverse backgrounds using a regimen of Upadacitinib extended-release tablets at a dosage of 15 mg orally once daily. The severity and treatment effect of each patient were assessed before and after treatment using the SALT (Severity of Alopecia Tool) method, 5 as recommended by the evaluation guidelines of the American Academy of Dermatology in the United States. Case 1: Male, 48 years old. The patient has experienced repeated hair loss from the scalp, eyebrows, and beard for the past 6 years. Currently, the patient has lost hair, eyebrows, and beard, revealing the scalp with visible follicle openings. Some of the nails were visible as pits, and there was no obvious damage to the toenails. The SALT score was 100. Additionally, the patient has experienced recurrent generalized itching for 40 years. Currently, scattered papules and brown hyperpigmentation are visible all over the body, particularly on the extremities. Despite trying various treatments (Table 1), the symptoms of hair loss and generalized itchy skin persisted. Complete the relevant auxiliary examinations, including blood routine, liver and kidney function, fec -Abstract Truncated-
dermatology